28
Oct
2025

Ningbo Menovo Pharmaceutical Co Ltd

Exhibitor at CPHI Frankfurt 2025 stand 12.1A88, API
About Us

CDMO/CMO and Generic API and FDF manufacturer with 5 cGMP inspected sites and strong R&D offering fast and competitive services and high quality products.

We handle Azides, Cyanation, Halogenation, Chiral and High-Pressure Hydrogenation, Multi-Chiral Heterocycles from gram to metric tons, from pre-clinical to commercial.


We have filled over 100 patents worldwide. We do Chemical Synthesis of APIs and Intermediates, Crystallization (Salts, Solvates and Polymorphs), Micronization and Solid State Characterization (XRPD, TGA, DVS, DSC,...

  • CN
  • 2022
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Pharmaceutical company
Primary activities
API Producer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Intermediates Manufacturer
Pharmaceutical Company (generic finished products)
Contact info
  • 12A-14/F Building 1, Ningbo R & D Park, No.999 Yangfan Road, Hi-Tech Zone, Ningbo, 315100, Zhejiang, China
Event information
CPHI Frankfurt 2025
  • 28 Oct 2025 - 30 Oct 2025
  • Messe, Frankfurt
  • Visit us at stand 12.1A88, API

Products Featured at CPHI Frankfurt 2025

  • Atorvastatin Ca

    Product Atorvastatin Ca

    Status: Commercial; Specification: EP,USP,CP;Submission of Regulations: EDMF, CEP, USDMF under preparing, CDMF.
  • Losartan Potassium

    Product Losartan Potassium

    Status: Commercial; Specification: EP, CP; Submission of Regulations: EDMF, CEP, USDMF, CDMF
  • Pregabalin

    Product Pregabalin

    Status: Commercial; Specification: EP, CP; Submission of Regulations:CEP under preparing, CDMF
  • Rosuvastatin Ca

    Product Rosuvastatin Ca

    Status: Commercial; Specification: EP, USP, CP; Submission of Regulations: EDMF, CEP, USDMF, CDMF.
  • Valsartan

    Product Valsartan

    Status: Commercial; Specification: EP,USP;Submission of Regulations:EDMF, CEP, USDMF, CDMF.